Experimental combo targets Hard-to-Treat stomach cancer

NCT ID NCT04768686

Completed Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a new drug, FLX475, combined with the immunotherapy pembrolizumab (Keytruda) in 20 people with advanced or metastatic stomach cancer. The goal was to see if the combination could shrink tumors in patients who had already tried other treatments. The study included two groups based on whether the cancer was linked to the Epstein-Barr virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FLX475 (tablet) and pembrolizumab (IV infusion)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced gastric cancer who have run out of standard therapies.
What could go wrong: This is a small, early-phase study with only 20 participants enrolled. The results may not apply to all patients, and the combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER

Contacts and locations

Locations

Asan Medical Center

Seoul, South Korea
Chonnam National University Hwasun Hospital

Hwasun, Jeollanam-do, South Korea
Gangnam Severance Hospital

Seoul, South Korea
Hanllym University Medical Center

Anyang-si, Gyeonggi-do, South Korea
Korea University Guro Hospital

Seoul, South Korea
Samsung Medical Center

Seoul, South Korea
Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea
Seoul National University Hospital

Seoul, South Korea
Severance Hospital

Seoul, South Korea
The Catholic University of Korea St. Vincent Hospital

Suwon, Gyeonggi-do, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.